Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Netarsudil 0.01%/latanoprost 0.005% · 1 trial · 2 indications
Intraocular pressure (IOP) will be measured with a Goldmann tonometer and recorded in millimeters mercury (mmHg). IOP will be calculated as the mean of two readings or the median of three readings at each timepoint.
| Arm | Type | Description |
|---|---|---|
| Reformulated PG324 | EXPERIMENTAL | One drop of netarsudil 0.01%/latanoprost 0.005% ophthalmic solution in each eye in the evening for three months |
| PG324 | ACTIVE_COMPARATOR | One drop of netarsudil 0.02%/latanoprost 0.005% ophthalmic solution in each eye in the evening for three months |
| Name | Type | Description |
|---|---|---|
| Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution | DRUG | Investigational ophthalmic solution |
| Netarsudil 0.02%/latanoprost 0.005% ophthalmic solution | DRUG | Commercially available ophthalmic solution |
Key Inclusion Criteria: * Diagnosis of open-angle glaucoma or ocular hypertension in both eyes; * Unmedicated intraocular pressure measurements in the study eye as specified in the protocol; * Corrected distance visual acuity equal to or better than 20/100 in the study eye. Key Exclusion Criteria:...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| AbbVie, Inc. | ABBV | 1 | PHASE1 | AGN-193408 |
| Glaukos Corp | GKOS | 1 | - | Travoprost |